Celgene Adds New Fusion Protein to Portfolio with Delinia Acquisition
The company will gain the rights to a mutein that is believed to help maintain immune system homeostasis.
Celgene will further bolster its capabilities in immunology and autoimmune disorders with the acquisition of the biotechnology company Delinia, a move Celgene announced on Jan. 26, 2017. With the company comes the ownership of DEL106, a novel IL-2 mutein Fc fusion protein that is designed to upregulate regulatory T cells (Tregs).
Tregs maintain tolerance to self-antigens and are instrumental in the prevention of autoimmune diseases. Thus, Tregs are immunosuppressive and work to downregulate induction and proliferation of effector T cells. The cytokine IL-2 normally activates effector cells, but also drives expansion of Tregs to regulate the effector cells.
Celgene will pay Delinia an initial payment of $300 million, with additional payments of up to $475 million upon the development, regulatory, and commercial advances related to DEL106. DEL-106 is expected to start clinical trials in 2018.
Source: Celgene
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
